Department of Microbiology and Immunology- Sydney Kimmel Medical College- Thomas Jefferson University, Philadelphia, PA, United States.
Department of Medical Genetics and Genomics, Children's Minnesota, Minneapolis, MN, United States.
Front Immunol. 2020 Oct 8;11:545414. doi: 10.3389/fimmu.2020.545414. eCollection 2020.
Neonatal hemophagocytic lymphohistiocytosis (HLH) is a medical emergency that can be associated with significant morbidity and mortality. Often these patients present with familial HLH (f-HLH), which is caused by gene mutations interfering with the cytolytic pathway of cytotoxic T-lymphocytes (CTLs) and natural killer cells. Here we describe a male newborn who met the HLH diagnostic criteria, presented with profound cholestasis, and carried a maternally inherited heterozygous mutation in [, c.568C>T (p.Arg190Cys)] in addition to a severe pathogenic variant in [, hemizygous c.1153T>C (Cys385Arg)]. Although mutations in gene are associated with f-HLH type 5, the clinical and biological relevance of the p.Arg190Cys mutation identified in this patient was uncertain. To assess its role in disease pathogenesis, we performed functional assays and biochemical and microscopic studies. We found that p.Arg190Cys mutation did not alter the expression or subcellular localization of STXBP2 or STX11, neither impaired the STXBP2/STX11 interaction. In contrast, forced expression of the mutated protein into normal CTLs strongly inhibited degranulation and reduced the cytolytic activity outcompeting the effect of endogenous wild-type STXBP2. Interestingly, arginine 190 is located in a structurally conserved region of STXBP2 where other f-HLH-5 mutations have been identified. Collectively, data strongly suggest that STXBP2-R190C is a deleterious variant that may act in a dominant-negative manner by probably stabilizing non-productive interactions between STXBP2/STX11 complex and other still unknown factors such as the membrane surface or Munc13-4 protein and thus impairing the release of cytolytic granules. In addition to the contribution of STXBP2-R190C to f-HLH, the accompanied mutation may have compounded the clinical symptoms; however, the extent by which deficiency has contributed to HLH in our patient remains unclear.
新生儿噬血细胞性淋巴组织细胞增生症(HLH)是一种医学急症,可导致严重的发病率和死亡率。这些患者通常表现为家族性 HLH(f-HLH),这是由基因突变干扰细胞毒性 T 淋巴细胞(CTL)和自然杀伤细胞的细胞溶解途径引起的。在这里,我们描述了一名符合 HLH 诊断标准的男性新生儿,表现为严重的胆汁淤积,并携带 [,c.568C>T(p.Arg190Cys)] 的母体遗传杂合突变,此外还携带 [,hemizygous c.1153T>C(Cys385Arg)] 的严重致病性变异。尽管 基因的突变与 f-HLH 类型 5 相关,但该患者中鉴定的 p.Arg190Cys 突变的临床和生物学相关性尚不确定。为了评估其在疾病发病机制中的作用,我们进行了功能测定以及生化和显微镜研究。我们发现,p.Arg190Cys 突变并未改变 STXBP2 或 STX11 的表达或亚细胞定位,也未损害 STXBP2/STX11 相互作用。相反,将突变蛋白强制表达到正常 CTL 中强烈抑制了脱颗粒,并降低了细胞毒性活性,从而削弱了内源性野生型 STXBP2 的作用。有趣的是,精氨酸 190 位于 STXBP2 的结构保守区域,在该区域已经发现了其他 f-HLH-5 突变。总的来说,数据强烈表明 STXBP2-R190C 是一种有害的变异体,可能通过稳定 STXBP2/STX11 复合物与其他未知因素(如膜表面或 Munc13-4 蛋白)之间的非生产性相互作用,从而阻碍细胞毒性颗粒的释放,以显性负性方式发挥作用。除了 STXBP2-R190C 对 f-HLH 的贡献外,伴随的 突变可能使临床症状更加复杂;然而, 缺乏对我们患者 HLH 的贡献程度尚不清楚。